MLC Medical LLC is pleased to announce the establishment of a strategic partnership with Celltrion Pharm, Inc., a leading South Korean biopharmaceutical company specializing in advanced biosimilars and biologic therapies.

As part of this collaboration, MLC Medical is expanding its portfolio with the registration of key biologic therapies in the Georgian market: Avtozma® (Tocilizumab), Yuflyma® (Adalimumab), and Stoboclo™ (Denosumab). These advanced biologics play a critical role in rheumatology, oncology, immunology, and the treatment of metabolic bone disorders.

The partnership with Celltrion Pharm reflects MLC Medical's ongoing commitment to introducing internationally recognized, high-quality medicines that address important healthcare needs in Georgia. By collaborating with trusted global manufacturers, we continue to strengthen our portfolio and improve patient access to advanced therapeutic solutions.

MLC Medical looks forward to a successful long-term collaboration with Celltrion Pharm and to supporting healthcare professionals with reliable, innovative products that meet the highest standards of quality, safety, and efficacy.